China SXT Pharmaceuticals (2RY3) Ratios
China SXT Pharmaceuticals Ratios
DE:2RY3's free cash flow for Q4 2026 was $-2.26M. For the 2026 fiscal year, DE:2RY3's free cash flow was increased by $0.00 and operating cash flow was $-2.26M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.93 | 3.54 | 1.60 | 1.35 | 1.31 |
| Quick Ratio | 7.25 | 3.40 | 1.51 | 1.31 | 1.25 |
| Cash Ratio | 6.48 | 3.01 | 1.36 | 1.20 | 0.91 |
| Solvency Ratio | -1.20 | -0.52 | -0.31 | -0.38 | -0.32 |
| Operating Cash Flow Ratio | -0.92 | -0.39 | -0.22 | -0.01 | 0.02 |
| Short-Term Operating Cash Flow Coverage | -9.49 | -3.30 | -0.84 | -0.02 | 0.13 |
| Net Current Asset Value | $ 29.46M | $ 15.07M | $ 5.04M | $ 4.66M | $ 5.33M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.05 | 0.11 | 0.13 | 0.06 |
| Debt-to-Equity Ratio | 0.04 | 0.06 | 0.19 | 0.26 | 0.12 |
| Debt-to-Capital Ratio | 0.04 | 0.06 | 0.16 | 0.20 | 0.11 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 |
| Financial Leverage Ratio | 1.17 | 1.40 | 1.66 | 2.01 | 2.04 |
| Debt Service Coverage Ratio | -14.63 | -1.89 | -0.83 | -1.37 | -2.58 |
| Interest Coverage Ratio | -113.13 | -4.14 | -4.62 | -11.76 | -141.43 |
| Debt to Market Cap | 0.01 | 0.00 | 0.21 | 0.23 | 0.04 |
| Interest Debt Per Share | 174.21 | 4.04 | 3.68 | 15.86 | 50.08 |
| Net Debt to EBITDA | 3.88 | 6.65 | 4.01 | 2.61 | 2.67 |
| Profitability Margins | |||||
| Gross Profit Margin | 17.09% | 21.11% | 28.73% | 21.62% | 48.10% |
| EBIT Margin | -664.06% | -152.53% | -132.45% | -276.82% | -206.41% |
| EBITDA Margin | -650.71% | -147.80% | -121.91% | -264.13% | -194.11% |
| Operating Profit Margin | -664.06% | -153.97% | -130.42% | -284.40% | -199.43% |
| Pretax Profit Margin | -566.29% | -189.77% | -160.67% | -301.00% | -207.82% |
| Net Profit Margin | -578.49% | -189.77% | -160.67% | -301.00% | -220.43% |
| Continuous Operations Profit Margin | -578.49% | -189.77% | -160.67% | -301.00% | -220.43% |
| Net Income Per EBT | 102.15% | 100.00% | 100.00% | 100.00% | 106.07% |
| EBT Per EBIT | 85.28% | 123.25% | 123.19% | 105.84% | 104.21% |
| Return on Assets (ROA) | -17.85% | -15.25% | -13.40% | -20.08% | -17.10% |
| Return on Equity (ROE) | -20.89% | -21.40% | -22.24% | -40.40% | -34.92% |
| Return on Capital Employed (ROCE) | -23.43% | -17.13% | -17.68% | -37.24% | -31.60% |
| Return on Invested Capital (ROIC) | -23.11% | -16.32% | -15.17% | -30.40% | -28.10% |
| Return on Tangible Assets | -17.86% | -15.26% | -13.41% | -20.10% | -17.12% |
| Earnings Yield | -6.79% | -0.03% | -26.90% | -39.19% | -12.31% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.33 | 0.92 | 1.43 | 1.47 | 0.47 |
| Payables Turnover | 1.79 | 1.19 | 1.07 | 1.12 | 0.91 |
| Inventory Turnover | 0.30 | 1.66 | 1.70 | 2.91 | 1.33 |
| Fixed Asset Turnover | 4.50 | 4.90 | 3.42 | 1.55 | 1.64 |
| Asset Turnover | 0.03 | 0.08 | 0.08 | 0.07 | 0.08 |
| Working Capital Turnover Ratio | 0.05 | 0.17 | 0.37 | 0.38 | 0.52 |
| Cash Conversion Cycle | 2108.92 | 310.63 | 130.09 | 48.96 | 649.44 |
| Days of Sales Outstanding | 1099.92 | 398.39 | 254.83 | 248.91 | 775.01 |
| Days of Inventory Outstanding | 1213.24 | 220.05 | 215.03 | 125.47 | 274.98 |
| Days of Payables Outstanding | 204.24 | 307.82 | 339.77 | 325.43 | 400.55 |
| Operating Cycle | 2313.17 | 618.44 | 469.86 | 374.38 | 1049.99 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -591.15 | -5.81 | -2.22 | -0.30 | 6.45 |
| Free Cash Flow Per Share | -591.15 | -5.81 | -2.23 | -0.57 | 4.95 |
| Dividend Paid and CapEx Coverage Ratio | -1004364.00 | -1159.33 | -272.98 | -1.14 | 4.29 |
| Capital Expenditure Coverage Ratio | -1004364.00 | -1159.33 | -272.98 | -1.14 | 4.29 |
| Operating Cash Flow Coverage Ratio | -3.58 | -2.38 | -0.73 | -0.02 | 0.13 |
| Operating Cash Flow to Sales Ratio | -3.75 | -1.35 | -1.00 | -0.04 | 0.10 |
| Free Cash Flow Yield | -4.40% | -0.02% | -16.80% | -1.00% | 0.44% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -14.72 | -3659.95 | -3.72 | -2.55 | -8.12 |
| Price-to-Sales (P/S) Ratio | 85.15 | 6946.22 | 5.97 | 7.68 | 17.90 |
| Price-to-Book (P/B) Ratio | 3.07 | 783.22 | 0.83 | 1.03 | 2.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -22.74 | -5151.63 | -5.95 | -99.99 | 226.34 |
| Price-to-Operating Cash Flow Ratio | -22.74 | -5156.08 | -5.97 | -187.51 | 173.62 |
| Price-to-Earnings Growth (PEG) Ratio | -1.27 | -28.34 | 0.04 | 0.03 | -0.18 |
| Enterprise Value Multiple | -9.21 | -4692.96 | -0.89 | -0.29 | -6.55 |
| Enterprise Value | 64.28M | 12.08B | 2.10M | 1.53M | 33.10M |
| EV to EBITDA | -9.21 | -4692.96 | -0.89 | -0.29 | -6.55 |
| EV to Sales | 59.93 | 6936.39 | 1.09 | 0.78 | 12.72 |
| EV to Free Cash Flow | -16.00 | -5144.34 | -1.08 | -10.11 | 160.85 |
| EV to Operating Cash Flow | -16.00 | -5148.78 | -1.09 | -18.96 | 123.39 |
| Tangible Book Value Per Share | 4370.38 | 38.20 | 16.04 | 54.92 | 393.98 |
| Shareholders’ Equity Per Share | 4371.31 | 38.22 | 16.06 | 55.03 | 394.91 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | 0.00 | 0.00 | 0.00 | -0.06 |
| Revenue Per Share | 157.83 | 4.31 | 2.22 | 7.39 | 62.57 |
| Net Income Per Share | -913.05 | -8.18 | -3.57 | -22.23 | -137.92 |
| Tax Burden | 1.02 | 1.00 | 1.00 | 1.00 | 1.06 |
| Interest Burden | 0.85 | 1.24 | 1.21 | 1.09 | 1.01 |
| Research & Development to Revenue | 0.17 | 0.11 | 0.10 | 0.00 | 0.00 |
| SG&A to Revenue | 6.64 | 1.75 | 1.37 | 2.86 | 2.12 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.18 | 0.28 | 0.90 |
| Income Quality | 0.65 | 0.71 | 0.62 | 0.01 | -0.05 |
Currency in USD
